Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Exelixis says Takeda receives approval for CABOMETYX in Japan » 08:03
11/27/20
11/27
08:03
11/27/20
08:03
EXEL

Exelixis

$18.74 /

+0.33 (+1.79%)

, TAK

Takeda Pharmaceutical

$17.72 /

+0.115 (+0.65%)

Exelixis (EXEL) announced…

Exelixis (EXEL) announced that Takeda Pharmaceutical Company (TAK), its partner responsible for the clinical development and commercialization of CABOMETYX in Japan, received approval from the Japanese Ministry of Health, Labor and Welfare to manufacture and market CABOMETYX as a treatment for patients with unresectable hepatocellular carcinoma that has progressed after prior systemic therapy. Takeda's application is based on the results of two clinical trials in patients with advanced HCC who had received prior systemic therapy: CELESTIAL, a global, randomized, placebo-controlled, double-blind phase 3 clinical trial, and Cabozantinib-2003, a phase 2 clinical trial conducted in Japan. The CELESTIAL trial was the basis for the CABOMETYX approvals in the U.S. and the EU for the treatment of patients with HCC who have been previously treated with sorafenib. Per the terms of Exelixis and Takeda's collaboration and license agreement, Exelixis is eligible to receive a $15M milestone payment from Takeda upon the first commercial sale of CABOMETYX for unresectable HCC, which is expected to occur in the fourth quarter of 2020. In January 2020, Takeda's application for approval to manufacture and sell CABOMETYX as a treatment for patients with unresectable HCC that had progressed after prior systemic therapy in Japan triggered a $10M milestone payment. Exelixis continues to be eligible to receive additional development, regulatory and first-sale milestones for potential future cabozantinib indications and is also eligible for sales revenue milestones and royalties on net sales of cabozantinib in Japan. Takeda fully funds cabozantinib development activities that are exclusively for the benefit of Japan and has the opportunity to share the costs associated with global cabozantinib clinical trials, providing the company opts into those trials.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$17.72 /

+0.115 (+0.65%)

EXEL Exelixis
$18.74 /

+0.33 (+1.79%)

EXEL Exelixis
$18.74 /

+0.33 (+1.79%)

10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
TAK Takeda Pharmaceutical
$17.72 /

+0.115 (+0.65%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
EXEL Exelixis
$18.74 /

+0.33 (+1.79%)

TAK Takeda Pharmaceutical
$17.72 /

+0.115 (+0.65%)

TAK Takeda Pharmaceutical
$17.72 /

+0.115 (+0.65%)

TAK Takeda Pharmaceutical
$17.72 /

+0.115 (+0.65%)

Wednesday
Hot Stocks
Arrowhead, Takeda Pharmaceutical close collaboration and license agreement » 07:33
11/25/20
11/25
07:33
11/25/20
07:33
ARWR

Arrowhead

$60.29 /

-7.915 (-11.61%)

, TAK

Takeda Pharmaceutical

$17.61 /

+0.005 (+0.03%)

Arrowhead (ARWR)…

Arrowhead (ARWR) announced that the collaboration and license agreement between Arrowhead and Takeda Pharmaceutical (TAK) announced on October 8, has now closed. Closing of the transaction was contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino, or HSR, Antitrust Improvements Act of 1976 in the U.S.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$17.61 /

+0.005 (+0.03%)

ARWR Arrowhead
$60.29 /

-7.915 (-11.61%)

ARWR Arrowhead
$60.29 /

-7.915 (-11.61%)

11/24/20 RBC Capital
Arrowhead price target raised to $80 from $62 at RBC Capital
11/24/20 Cantor Fitzgerald
Arrowhead price target raised to $80 from $58 at Cantor Fitzgerald
11/19/20
Fly Intel: Top five analyst initiations
11/19/20 Citi
Arrowhead initiated with a Buy at Citi
TAK Takeda Pharmaceutical
$17.61 /

+0.005 (+0.03%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
ARWR Arrowhead
$60.29 /

-7.915 (-11.61%)

  • 04
    Dec
TAK Takeda Pharmaceutical
$17.61 /

+0.005 (+0.03%)

TAK Takeda Pharmaceutical
$17.61 /

+0.005 (+0.03%)

ARWR Arrowhead
$60.29 /

-7.915 (-11.61%)

TAK Takeda Pharmaceutical
$17.61 /

+0.005 (+0.03%)

ARWR Arrowhead
$60.29 /

-7.915 (-11.61%)

Over a week ago
Conference/Events
Takeda Pharmaceutical participates in a conference call with Cowen » 16:25
11/19/20
11/19
16:25
11/19/20
16:25
TAK

Takeda Pharmaceutical

$17.46 /

+0.075 (+0.43%)

Healthcare Analyst…

Healthcare Analyst Cacciatore holds a conference call with management on November 19 at 5 pm hosted by Cowen.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$17.46 /

+0.075 (+0.43%)

TAK Takeda Pharmaceutical
$17.46 /

+0.075 (+0.43%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
TAK Takeda Pharmaceutical
$17.46 /

+0.075 (+0.43%)

TAK Takeda Pharmaceutical
$17.46 /

+0.075 (+0.43%)

TAK Takeda Pharmaceutical
$17.46 /

+0.075 (+0.43%)

Conference/Events
Takeda Pharmaceutical participates in a conference call with Cowen » 04:55
11/19/20
11/19
04:55
11/19/20
04:55
TAK

Takeda Pharmaceutical

$17.39 /

+0.025 (+0.14%)

Healthcare Analyst…

Healthcare Analyst Cacciatore holds a conference call with management on November 19 at 5 pm hosted by Cowen.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$17.39 /

+0.025 (+0.14%)

TAK Takeda Pharmaceutical
$17.39 /

+0.025 (+0.14%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
TAK Takeda Pharmaceutical
$17.39 /

+0.025 (+0.14%)

TAK Takeda Pharmaceutical
$17.39 /

+0.025 (+0.14%)

TAK Takeda Pharmaceutical
$17.39 /

+0.025 (+0.14%)

Hot Stocks
Paulson & Co. buys Lear, cuts Tiffany in Q3 » 16:52
11/16/20
11/16
16:52
11/16/20
16:52
LEA

Lear

$140.81 /

+2.79 (+2.02%)

, ENDP

Endo

$5.03 /

+0.235 (+4.90%)

, GOLD

Barrick Gold

$25.85 /

-0.05 (-0.19%)

, TCO

Taubman Centers

$42.80 /

+3.3 (+8.35%)

, SSRM

SSR Mining

$19.21 /

-0.495 (-2.51%)

, THM

International Tower Hill Mines

$1.49 /

-0.01 (-0.67%)

, TIF

Tiffany

$131.50 /

+0.135 (+0.10%)

, TAK

Takeda Pharmaceutical

$17.26 /

-0.04 (-0.23%)

, QGEN

Qiagen

$46.27 /

-1.46 (-3.06%)

, PCRX

Pacira

$64.25 /

+0.59 (+0.93%)

, HZNP

Horizon Therapeutics

$70.85 /

-1.49 (-2.06%)

, BHC

Bausch Health

$19.92 /

+0.32 (+1.63%)

, GLD

SPDR Gold Shares

$177.10 /

-0.08 (-0.05%)

, NG

NovaGold

$10.99 /

+0.14 (+1.29%)

, BSIG

BrightSphere

$18.14 /

+0.45 (+2.54%)

John Paulson's…

John Paulson's Paulson & Co. disclosed in an SEC filing its holdings as of September 30, 2020. Paulson's two new buys in the quarter included Lear (LEA). The fund increased its stake in five holdings, including by size of previous position Endo (ENDP), Barrick Gold (GOLD), Taubman Centers (TCO), SSR Mining (SSRM), and International Tower Hill Mines (THM). Paulson reduced its stake in six holdings, including by size of previous position Tiffany (TIF), Takeda Pharmaceuticals (TAK), Qiagen (QGEN), Pacira Biosciences (PCRX), and Horizon Therapeutics (HZNP). The fund's top holdings as of September 30, 2020, in order of size, were Horizon Therapeutics, Bausch Health (BHC), SPDR Gold Shares (GLD), Novagold Resources (NG), and Brightsphere Investment Group (BSIG).

ShowHide Related Items >><<
TIF Tiffany
$131.50 /

+0.135 (+0.10%)

TCO Taubman Centers
$42.80 /

+3.3 (+8.35%)

TAK Takeda Pharmaceutical
$17.26 /

-0.04 (-0.23%)

SSRM SSR Mining
$19.21 /

-0.495 (-2.51%)

QGEN Qiagen
$46.27 /

-1.46 (-3.06%)

PCRX Pacira
$64.25 /

+0.59 (+0.93%)

NG NovaGold
$10.99 /

+0.14 (+1.29%)

LEA Lear
$140.81 /

+2.79 (+2.02%)

HZNP Horizon Therapeutics
$70.85 /

-1.49 (-2.06%)

GOLD Barrick Gold
$25.85 /

-0.05 (-0.19%)

GLD SPDR Gold Shares
$177.10 /

-0.08 (-0.05%)

ENDP Endo
$5.03 /

+0.235 (+4.90%)

BSIG BrightSphere
$18.14 /

+0.45 (+2.54%)

BHC Bausch Health
$19.92 /

+0.32 (+1.63%)

LEA Lear
$140.81 /

+2.79 (+2.02%)

11/09/20
Fly Intel: Top five analyst upgrades
11/09/20 Morgan Stanley
Lear upgraded to Overweight from Equal Weight at Morgan Stanley
11/02/20 Benchmark
Lear price target raised to $162 from $130 at Benchmark
10/22/20 JPMorgan
Lear price target raised to $149 from $125 at JPMorgan
ENDP Endo
$5.03 /

+0.235 (+4.90%)

10/20/20 H.C. Wainwright
BioSpecifics downgraded to Neutral from Buy at H.C. Wainwright
10/05/20 Piper Sandler
Piper reiterates Overweight on Endo after dermatologist survey
09/25/20 Raymond James
Endo deal could generate $50M-$75M in cash inflow, says Raymond James
07/27/20 Goldman Sachs
Endo initiated with a Sell at Goldman Sachs
GOLD Barrick Gold
$25.85 /

-0.05 (-0.19%)

10/22/20 National Bank
Barrick Gold price target lowered to C$42 from C$44 at National Bank
09/17/20 Jefferies
Freeport 'not an acquisition target for now,' says Jefferies
09/11/20 National Bank
Barrick Gold price target raised to C$44 from C$42 at National Bank
08/12/20 Canaccord
Barrick Gold upgraded to Buy from Hold at Canaccord
TCO Taubman Centers
$42.80 /

+3.3 (+8.35%)

11/16/20 Mizuho
Simon Property price target raised to $74 from $66 at Mizuho
11/16/20 Piper Sandler
Taubman Centers upgraded to Neutral from Underweight at Piper Sandler
09/09/20 Deutsche Bank
Deutsche closes near-term sell idea on Taubman Centers
07/01/20 Goldman Sachs
Taubman Centers assumed with Not Rated at Goldman Sachs
SSRM SSR Mining
$19.21 /

-0.495 (-2.51%)

10/22/20 National Bank
SSR Mining price target lowered to C$45 from C$46 at National Bank
10/13/20 Scotiabank
SSR Mining price target raised to C$39.50 from C$36 at Scotiabank
09/21/20 Canaccord
Canaccord maintains Buy on SSR Mining following merger with Alacer Gold
09/17/20 National Bank
SSR Mining coverage resumed with an Outperform at National Bank
THM International Tower Hill Mines
$1.49 /

-0.01 (-0.67%)

10/05/20 B. Riley Securities
B. Riley starts International Tower Hill Mines with Buy, $5 price target
10/05/20 B. Riley Securities
International Tower Hill Mines initiated with a Buy at B. Riley Securities
TIF Tiffany
$131.50 /

+0.135 (+0.10%)

10/28/20
LVMH, Tiffany near agreement on $131.50 per share price, WSJ reports
10/16/20 William Blair
Tiffany results strengthen legal standing against LVMH, says William Blair
09/10/20 Wells Fargo
Tiffany price target lowered to $120 from $135 at Wells Fargo
08/25/20 Oppenheimer
Opco 'turning more concerned' LVMH could reduce Tiffany buyout price
TAK Takeda Pharmaceutical
$17.26 /

-0.04 (-0.23%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
QGEN Qiagen
$46.27 /

-1.46 (-3.06%)

11/04/20 Berenberg
Qiagen price target raised to EUR 52 from EUR 50 at Berenberg
10/06/20 BofA
Qiagen resumed with Buy at BofA
10/06/20 BofA
Qiagen upgraded to Buy from Neutral at BofA
10/05/20 Citi
Citi opens 'positive catalyst watch' on Qiagen ahead of Q3 results
PCRX Pacira
$64.25 /

+0.59 (+0.93%)

09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
09/21/20 Northland
Pacira upgraded to Outperform from Market Perform at Northland
08/14/20 Truist
Pacira price target raised to $65 from $54 at Truist
HZNP Horizon Therapeutics
$70.85 /

-1.49 (-2.06%)

11/03/20 BMO Capital
Horizon Therapeutics price target raised to $110 from $105 at BMO Capital
11/03/20 Citi
Horizon Therapeutics price target raised to $116 from $112 at Citi
10/14/20 Stifel
Horizon expected to meet or exceed Q3, 2020 expectations, says Stifel
10/01/20 Stifel
Stifel halves Selecta Biosciences target to $2, sees 'no reason to buy here'
BHC Bausch Health
$19.92 /

+0.32 (+1.63%)

11/05/20 Piper Sandler
Bausch Health price target lowered to $25 from $26 at Piper Sandler
10/26/20 Barclays
Bausch Health price target raised to $29 from $28 at Barclays
09/17/20
Fly Intel: Top five analyst upgrades
09/17/20 BofA
Bausch Health upgraded to Neutral from Underperform at BofA
GLD SPDR Gold Shares
$177.10 /

-0.08 (-0.05%)

NG NovaGold
$10.99 /

+0.14 (+1.29%)

BSIG BrightSphere
$18.14 /

+0.45 (+2.54%)

07/29/20 BofA
BrightSphere upgraded to Neutral from Underperform at BofA
07/28/20 Keefe Bruyette
BrightSphere upgraded to Outperform from Market Perform at Keefe Bruyette
05/12/20 Morgan Stanley
BrightSphere upgraded to Equal Weight from Underweight at Morgan Stanley
04/08/20 Morgan Stanley
BrightSphere downgraded to Underweight at Morgan Stanley
TIF Tiffany
$131.50 /

+0.135 (+0.10%)

TCO Taubman Centers
$42.80 /

+3.3 (+8.35%)

SSRM SSR Mining
$19.21 /

-0.495 (-2.51%)

QGEN Qiagen
$46.27 /

-1.46 (-3.06%)

PCRX Pacira
$64.25 /

+0.59 (+0.93%)

LEA Lear
$140.81 /

+2.79 (+2.02%)

HZNP Horizon Therapeutics
$70.85 /

-1.49 (-2.06%)

GOLD Barrick Gold
$25.85 /

-0.05 (-0.19%)

ENDP Endo
$5.03 /

+0.235 (+4.90%)

BSIG BrightSphere
$18.14 /

+0.45 (+2.54%)

BHC Bausch Health
$19.92 /

+0.32 (+1.63%)

  • 07
    Aug
TIF Tiffany
$131.50 /

+0.135 (+0.10%)

TAK Takeda Pharmaceutical
$17.26 /

-0.04 (-0.23%)

SSRM SSR Mining
$19.21 /

-0.495 (-2.51%)

QGEN Qiagen
$46.27 /

-1.46 (-3.06%)

LEA Lear
$140.81 /

+2.79 (+2.02%)

GOLD Barrick Gold
$25.85 /

-0.05 (-0.19%)

ENDP Endo
$5.03 /

+0.235 (+4.90%)

BSIG BrightSphere
$18.14 /

+0.45 (+2.54%)

TIF Tiffany
$131.50 /

+0.135 (+0.10%)

TCO Taubman Centers
$42.80 /

+3.3 (+8.35%)

TAK Takeda Pharmaceutical
$17.26 /

-0.04 (-0.23%)

QGEN Qiagen
$46.27 /

-1.46 (-3.06%)

PCRX Pacira
$64.25 /

+0.59 (+0.93%)

NG NovaGold
$10.99 /

+0.14 (+1.29%)

HZNP Horizon Therapeutics
$70.85 /

-1.49 (-2.06%)

GOLD Barrick Gold
$25.85 /

-0.05 (-0.19%)

ENDP Endo
$5.03 /

+0.235 (+4.90%)

BHC Bausch Health
$19.92 /

+0.32 (+1.63%)

TIF Tiffany
$131.50 /

+0.135 (+0.10%)

TCO Taubman Centers
$42.80 /

+3.3 (+8.35%)

TAK Takeda Pharmaceutical
$17.26 /

-0.04 (-0.23%)

SSRM SSR Mining
$19.21 /

-0.495 (-2.51%)

QGEN Qiagen
$46.27 /

-1.46 (-3.06%)

NG NovaGold
$10.99 /

+0.14 (+1.29%)

GOLD Barrick Gold
$25.85 /

-0.05 (-0.19%)

ENDP Endo
$5.03 /

+0.235 (+4.90%)

BSIG BrightSphere
$18.14 /

+0.45 (+2.54%)

BHC Bausch Health
$19.92 /

+0.32 (+1.63%)

GLD SPDR Gold Shares
$177.10 /

-0.08 (-0.05%)

Conference/Events
Takeda Pharmaceutical participates in a conference call with Cowen » 16:03
11/16/20
11/16
16:03
11/16/20
16:03
TAK

Takeda Pharmaceutical

$17.23 /

-0.07 (-0.40%)

Healthcare Analyst…

Healthcare Analyst Cacciatore holds a conference call with management on November 19 at 5 pm hosted by Cowen.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$17.23 /

-0.07 (-0.40%)

TAK Takeda Pharmaceutical
$17.23 /

-0.07 (-0.40%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
TAK Takeda Pharmaceutical
$17.23 /

-0.07 (-0.40%)

TAK Takeda Pharmaceutical
$17.23 /

-0.07 (-0.40%)

TAK Takeda Pharmaceutical
$17.23 /

-0.07 (-0.40%)

Hot Stocks
Xoma earns $2M milestone from Takeda Pharmaceutical » 08:04
11/16/20
11/16
08:04
11/16/20
08:04
XOMA

Xoma

$29.12 /

+1.12 (+4.00%)

, TAK

Takeda Pharmaceutical

$17.30 /

+0.41 (+2.43%)

XOMA Corporation (XOMA)…

XOMA Corporation (XOMA) announced it has earned a $2M milestone payment from Takeda Pharmaceutical Company Limited (TAK) as the first patient has been dosed in its Phase 2 study to evaluate safety, tolerability, and efficacy of mezagitamab in participants with generalized myasthenia gravis. In 2006, XOMA and Takeda entered into a collaboration agreement to identify potential therapeutic antibodies that Takeda would advance into clinical development. Mezagitamab is an anti-CD38 antibody that resulted from the companies' collaboration. XOMA may receive up to $16 million in additional milestones from Takeda. Upon receipt of regulatory approval to commercialize mezagitamab, XOMA will receive a four percent royalty on any net product sales.

ShowHide Related Items >><<
XOMA Xoma
$29.12 /

+1.12 (+4.00%)

TAK Takeda Pharmaceutical
$17.30 /

+0.41 (+2.43%)

XOMA Xoma
$29.12 /

+1.12 (+4.00%)

03/10/20 H.C. Wainwright
Novartis' recent R&D day driving interest in Xoma, says H.C. Wainwright
TAK Takeda Pharmaceutical
$17.30 /

+0.41 (+2.43%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
XOMA Xoma
$29.12 /

+1.12 (+4.00%)

TAK Takeda Pharmaceutical
$17.30 /

+0.41 (+2.43%)

TAK Takeda Pharmaceutical
$17.30 /

+0.41 (+2.43%)

TAK Takeda Pharmaceutical
$17.30 /

+0.41 (+2.43%)

Hot Stocks
Arrowhead announces interim clinical data from AROAAT2002 trial » 09:07
11/13/20
11/13
09:07
11/13/20
09:07
ARWR

Arrowhead

$69.20 /

-0.33 (-0.47%)

, TAK

Takeda Pharmaceutical

$16.89 /

-0.42 (-2.43%)

Arrowhead (ARWR)…

Arrowhead (ARWR) announced interim clinical data from AROAAT2002, an open-label Phase 2 clinical study of ARO-AAT, the company's second-generation investigational RNA interference, or RNAi, therapeutic being developed as a treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency, or AATD. The data demonstrate that three doses of ARO-AAT over 24-weeks resulted in consistent reductions of the disease-causing mutant Z protein and improvements in clinically relevant biomarkers of liver disease. The results were presented in a late-breaking poster at the annual meeting of the American association for the Study of Liver Disease, or AASLD. In the AROAAT2002 study, four patients with homozygous PiZZ alpha-1 antitrypsin deficiency and evidence of fibrosis at screening, each received three doses of ARO-AAT on week 0, 4 and 16. Liver biopsies were performed at screening and at week 24. Assessments included safety, changes in serum Z-AAT, liver Z-AAT, ALT, GGT, Pro-C3, liver elastography and liver globule assessment. Additional histologic adjudication is ongoing. Serum Z-AAT reductions were 86%-93%. Total intra-hepatic Z-AAT reductions were 72%-95%. All patients demonstrated greater than 80% reduction in liver Z-AAT monomer. Overall, 3 of 4 patients demonstrated reductions in Z-AAT polymer with a range of 68%-97% and 3 of 4 patients had a decrease in liver globule involvement and one subject remained unchanged. All patients showed reductions in ALT and in GGT. In the study, 3 of 4 patients demonstrated a substantial reduction of greater than 20% in FibroScan values and 3 of 4 patients showed greater than 30% reduction in serum Pro-C3, a marker of fibrogenesis. Overall, ARO-AAT 200 mg as a subcutaneous injection was well tolerated in PiZZ AATD subjects. One treatment emergent SAE of Epstein bar virus related myocarditis was reported. No treatment emergent AEs related to change in pulmonary status or pulmonary function were reported. No clinically meaningful changes in ppFEV1 from baseline to Week 24 were observed. In October, Arrowhead and Takeda Pharmaceutical (TAK) announced a collaboration and licensing agreement to develop ARO-AAT. Under the terms of the agreement, Arrowhead and Takeda will co-develop ARO-AAT which, if approved, will be co-commercialized in the U.S. under a 50/50 profit-sharing structure. Outside the U.S., Takeda will lead the global commercialization strategy and receive an exclusive license to commercialize ARO-AAT with Arrowhead eligible to receive tiered royalties of 20%-25% on net sales. Arrowhead will receive an upfront payment of $300M and is eligible to receive potential development, regulatory and commercial milestones up to $740M. Closing of the transaction is contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$16.89 /

-0.42 (-2.43%)

ARWR Arrowhead
$69.20 /

-0.33 (-0.47%)

ARWR Arrowhead
$69.20 /

-0.33 (-0.47%)

10/12/20 B. Riley Securities
Arrowhead price target raised to $68 from $57 at B. Riley Securities
10/08/20 Piper Sandler
Arrowhead price target raised to $90 from $80 at Piper Sandler
09/16/20 Chardan
Arrowhead biopsy data for ARO-AAT 'impressive,' says Chardan
09/16/20 B. Riley Securities
Arrowhead releases 'extremely compelling' Phase II results, says B. Riley FBR
TAK Takeda Pharmaceutical
$16.89 /

-0.42 (-2.43%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
ARWR Arrowhead
$69.20 /

-0.33 (-0.47%)

  • 04
    Dec
TAK Takeda Pharmaceutical
$16.89 /

-0.42 (-2.43%)

TAK Takeda Pharmaceutical
$16.89 /

-0.42 (-2.43%)

ARWR Arrowhead
$69.20 /

-0.33 (-0.47%)

TAK Takeda Pharmaceutical
$16.89 /

-0.42 (-2.43%)

Hot Stocks
Zhongchao, Takeda Pharmaceutical expand scope of cooperation in China » 06:34
11/12/20
11/12
06:34
11/12/20
06:34
ZCMD

Zhongchao

$1.90 /

+0.08 (+4.40%)

, TAK

Takeda Pharmaceutical

$17.30 /

+0.23 (+1.35%)

Zhongchao (ZCMD)…

Zhongchao (ZCMD) announced that the company and Takeda Pharmaceutical (TAK) agreed to expand their current scope of cooperation which now covers five of Takeda's subsidiaries in China including the new addition of Baishen Biotechnology. Pursuant to the amended service agreement by and between Zhongchao and Takeda, Zhongchao shall continue to serve as Takeda's vendor and partner in China, providing a broad range of services in medical editing, document collation, and medical training and education to Takeda.

ShowHide Related Items >><<
ZCMD Zhongchao
$1.90 /

+0.08 (+4.40%)

TAK Takeda Pharmaceutical
$17.30 /

+0.23 (+1.35%)

ZCMD Zhongchao
$1.90 /

+0.08 (+4.40%)

TAK Takeda Pharmaceutical
$17.30 /

+0.23 (+1.35%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
TAK Takeda Pharmaceutical
$17.30 /

+0.23 (+1.35%)

TAK Takeda Pharmaceutical
$17.30 /

+0.23 (+1.35%)

TAK Takeda Pharmaceutical
$17.30 /

+0.23 (+1.35%)

Hot Stocks
Takeda Pharmaceutical, OrigiMed partner for R&D in clinical treatment platform » 08:32
11/11/20
11/11
08:32
11/11/20
08:32
TAK

Takeda Pharmaceutical

$17.07 /

+0.265 (+1.58%)

Takeda and OrigiMed, a…

Takeda and OrigiMed, a China-based precision medicine company, announced their strategic partnership to develop a genomic-based precision medicine platform during the 3rd China International Import Expo. With joint efforts, such a platform is believed to accelerate the R&D and commercialization of innovative medicines. Under the terms of the agreement, OrigiMed will provide its "one-stop" commercialized solution by leveraging its genomic datasets and sequencing technology to accelerate innovative and precision medicines development. Takeda plans to bring over 15 innovative drugs to Chinese market in the next five years.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$17.07 /

+0.265 (+1.58%)

TAK Takeda Pharmaceutical
$17.07 /

+0.265 (+1.58%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
TAK Takeda Pharmaceutical
$17.07 /

+0.265 (+1.58%)

TAK Takeda Pharmaceutical
$17.07 /

+0.265 (+1.58%)

TAK Takeda Pharmaceutical
$17.07 /

+0.265 (+1.58%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.